Showing results (31-40 of 302) with videos related to
Sort By:
Pageof 31
Cancers|November 13, 2021
Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to ImmunotherapyMarisa Schmitt, Tobias Sinnberg, Heike Niessner, et al.Oncotarget|October 23, 2018
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter studyJulia K Tietze, Andrea Forschner, Carmen Loquai, et al.Journal of Translational Medicine|August 27, 2025
GeneBits: ultra-sensitive tumour-informed ctDNA monitoring of treatment response and relapse in cancer patientsJulian Broche, Olga Kelemen, Aishwarya Sekar, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 9, 2009
G-DRG Version 2009: new developmentsMarcel L Müller, Andrea Forschner, Andreas Wenke, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|August 6, 2021
Is there an overtreatment of melanoma patients at the end of their life? Results of a multicenter study on 193 melanoma patientsAndrea Forschner, Carmen Loquai, Frank Meiss, et al.The Australasian Journal of Dermatology|February 13, 2020
Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsyNikolaus B Wagner, Felix Luttermann, Maximilian Gassenmaier, et al.Cell Death & Disease|September 13, 2018
Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugsElena Makino, Vanessa Gutmann, Corinna Kosnopfel, et al.Frontiers in Oncology|May 19, 2023
Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case reportSelina Reiter, Christopher Schroeder, Julian Broche, et al.Therapeutic Advances in Medical Oncology|April 2, 2025
Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2Markus Reitmajer, Lena Nanz, Nina Müller, et al.Der Pathologe|March 25, 2020
[Malignant melanoma]Georg Lodde, Lisa Zimmer, Elisabeth Livingstone, et al.Pageof 31